Report
Patient-Led Commercial Targeting
in Multiple Sclerosis (Neurology)
A global biopharma company preparing to launch a new treatment for Relapsing Multiple Sclerosis (RMS) faced a commercial targeting challenge: patients often first present with vague neurological symptoms to primary care providers or eye specialists, leading to delays in diagnosis and treatment. Traditional prescribing-focused models overlooked these early influencers. By leveraging DRG Fusion, which maps real-world patient journeys and integrates data across specialties, the company was able to uncover referral pathways, identify high-impact healthcare providers (HCPs) beyond neurologists, and optimize targeting strategies. This approach enabled earlier diagnosis, better care coordination, and more efficient resource allocation.
Key Takeaways:
Learn how DRG Fusion maps real-world patient journeys to reveal care gaps and referral patterns in RMS.
Understand why early influencers—like PCPs and ophthalmologists—are critical to commercial strategy.
Discover how integrating longitudinal, cross-specialty data enhances targeting beyond prescribing behaviors.
See how enhanced segmentation and provider mapping reduce diagnostic delays and improve therapy initiation.
Explore a coordinated, multi-specialty approach to drive commercial efficiency and patient access.
